Filing Analysis
Cosmos Health Inc. released its financial results for the second fiscal quarter and six months ended June 30, 2026. The company reported record revenue and significant improvements in gross profit and equity.
📋 Key Facts
- Q2 2026 Revenue: $19.0M (up 29% YoY).
- H1 2026 Revenue: $36.9M (up 30% YoY).
- Q2 Adjusted Gross Profit increased by 58%.
- Total Liabilities reduced by 13%.
- Stockholders' Equity increased by 12%.
- A $5M share repurchase program is currently underway.
Cosmos Health Inc. held its 2026 Annual Meeting of Stockholders on July 15, 2026, where shareholders approved several key items including the election of directors and the issuance of Series B Preferred Stock.
🚩 Red Flags
- Approval of Series B Preferred Stock issuance often indicates a need for capital, potentially dilutive to common shareholders.
📋 Key Facts
- Annual Meeting held on July 15, 2026; approximately 47% of outstanding shares were represented (28,315,417 shares).
- Stockholders approved the designation and issuance of 100,000 shares of Series B Preferred Stock.
- Six directors were elected to serve until the next Annual Meeting: Grigorios Siokas, Demetrios G. Demetriades, John J. Hoidas, Dr. Anastasios Aslidis, Suhel Bhutawala, and Theodoros C. Karkantzos.
- The 2026 Equity Omnibus Plan was approved by stockholders (79.58% affirmative).
- Ratification of the appointment of the Company's Independent Registered Public Accounting Firm was approved (84.24% affirmative).
Cosmos Health Inc. has authorized a $5 million share repurchase program to be executed over the next six months, ending December 31, 2026. The company also approved the use of Rule 10b5-1 trading plans to facilitate these repurchases.
📋 Key Facts
- Board authorized a share repurchase program for up to $5 million of common stock.
- The program is scheduled to run for 6 months, ending on December 31, 2026.
- Repurchases will be conducted via open market, private negotiations, or block purchases.
- The company authorized the use of Rule 10b5-1 trading plans to manage repurchase timing.
Cosmos Health Inc. reported its Q1 2026 financial results, highlighting a 31% increase in revenue to $17.9 million and a $4.5 million reduction in total liabilities. The company also noted that stockholders' equity increased by 7.6% and cash reserves stood at $2.2 million.
📋 Key Facts
- Q1 2026 revenue increased by 31% year-over-year to $17.9 million, setting a new Q1 record.
- Total liabilities were reduced by $4.5 million.
- Stockholders' equity increased by 7.6%.
- Cash balance was reported at $2.2 million as of March 31, 2026.
- The company announced that its U.S. expansion is currently underway.
Cosmos Health reported record financial results for the fiscal year ended December 31, 2025, highlighted by a 20% revenue increase to $65.3 million and an 83% surge in gross profit. The company also demonstrated significant operational improvement with a 418 basis point expansion in gross margins and a 10x increase in its cash position.
📋 Key Facts
- Full year 2025 revenue reached an all-time record of $65.3 million, representing 20% year-over-year growth.
- Gross profit increased 83% to $7.9 million for the fiscal year.
- Gross margin expanded by 418 basis points compared to the prior period.
- Adjusted EPS showed an 82% improvement.
- The company's cash position grew 10x to $3.5 million as of December 31, 2025.
- Management reported that record growth has continued into the first part of 2026 across all core segments.
Cosmos Health Inc. received a non-compliance notice from Nasdaq for failing to maintain the minimum $1.00 bid price requirement. The company has 180 days to regain compliance and explicitly stated its intention to perform a reverse stock split if necessary.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to maintain minimum bid price (Penny Stock risk)
- Explicit mention of an impending reverse stock split
📋 Key Facts
- Received non-compliance letter from Nasdaq on December 11, 2025.
- Failure to maintain minimum bid price of $1.00 per share for 30 consecutive business days (Nasdaq Listing Rule 5550(a)(2)).
- Company has a 180-calendar day grace period from December 11, 2025, to regain compliance.
- Compliance requires maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
- The Company explicitly stated its intent to effect a reverse stock split if it cannot otherwise regain compliance.
Cosmos Health Inc. filed an 8-K to announce its quarterly and nine-month financial results for the period ended September 30, 2025. The filing serves as a formal disclosure of recent operational performance via a press release.
📋 Key Facts
- Reporting date: November 17, 2025
- Period covered: Quarter and nine months ended September 30, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Signed by Georgios Terzis, Chief Financial Officer
Cosmos Health Inc. has successfully regained compliance with the Nasdaq Minimum Bid Price Requirement (Rule 5550(a)(2)). The company's stock maintained a closing bid price of $1.00 or greater for at least 18 consecutive business days, ending October 15, 2025.
🚩 Red Flags
- Historical non-compliance: The company has been under threat of delisting due to low stock price since November 2024.
- Volatility risk: Maintaining compliance requires sustained price action above the $1.00 threshold.
📋 Key Facts
- The company was previously non-compliant with Nasdaq Listing Rule 5550(a)(2) since November 6, 2024.
- Compliance requirement: Minimum bid price must be at least $1.00 for the previous 30 consecutive business days.
- Compliance achieved: Closing bid price was at or above $1.00 from September 22, 2025, to October 15, 2025 (at least 18 consecutive business days).
- The matter regarding the minimum bid price requirement is now officially closed by Nasdaq Staff.
Cosmos Health Inc. announced the appointment of Theodoros C. Karkantzos to its Board of Directors and the Nominating and Corporate Governance Committee, effective September 30, 2025.
🚩 Red Flags
- Related-party context: The appointee was a consultant for the company through his own firm (C Capital Media Ltd.) immediately prior to joining the board.
📋 Key Facts
- Theodoros C. Karkantzos appointed to the Board effective September 30, 2025.
- Appointed to the Nominating and Corporate Governance Committee.
- Compensation includes a $5,000 cash fee for committee participation and a $10,000 annual board participation fee.
- Will receive equity grants under the Company’s 2025 Omnibus Incentive Plan.
- Karkantzos previously provided consulting services via C Capital Media Ltd. from July 1, 2024, to August 28, 2025, without cash or equity compensation.
Cosmos Health Inc. held its 2025 Annual Meeting of Stockholders where shareholders approved several critical measures, including authorization for a discretionary reverse stock split and an increase in authorized shares.
🚩 Red Flags
- Approval of a reverse stock split (Proposal 2) often indicates an attempt to regain compliance with minimum bid price requirements for Nasdaq listing.
- Significant increase in authorized shares (up to 1.5 billion common and 300 million preferred) suggests potential future dilution via equity offerings.
📋 Key Facts
- Annual Meeting held on September 30, 2025; approximately 53% of total outstanding shares were represented (15,983,371 shares).
- Shareholders approved Proposal 2: Authorization of the Board to effect a reverse stock split at their discretion.
- Shareholders approved Proposal 8: Amendment to increase authorized Common Stock to 1.5 billion shares and 'blank check' Preferred Stock to 300 million shares.
- Shareholders approved Proposal 3: Issuance of shares issuable upon conversion of Notes in compliance with Nasdaq Listing Rule 5635(d).
- Six directors were elected to serve until the next Annual Meeting.
Cosmos Health Inc. has filed an 8-K to furnish its Chief Executive Officer's annual letter to shareholders for the year ended December 31, 2024.
📋 Key Facts
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- The primary content is a CEO annual letter dated September 29, 2025, regarding the fiscal year ended December 31, 2024.
- The information is 'furnished' rather than 'filed', meaning it is not subject to Section 18 liability of the Exchange Act.
Cosmos Health Inc. has consummated the initial closing of an $8,000,000 senior secured convertible promissory note issuance to an institutional investor. The note features a 9% interest rate (increasing to 16% upon default) and allows for conversion at a price based on the lower of $1.05 or the market price.
🚩 Red Flags
- Senior secured status: The note ranks ahead of existing debt, potentially diluting or subordinating current creditors/equity holders.
- Death Spiral Provision: The conversion price is tied to the 'lower of' $1.05 or Market Price, which can lead to massive dilution if the stock price drops.
- Penalty Interest: A significant jump in interest rate (from 9% to 16%) occurs upon default.
- High Dilution Risk: Interest is payable in shares of common stock unless the company elects to pay cash.
📋 Key Facts
- Consummated initial closing of an $8,000,000 senior secured convertible promissory note on August 7, 2025.
- The note bears a 9% annual interest rate, payable in shares or cash (at company option).
- Interest rate increases to 16% per annum upon an Event of Default.
- Conversion price is the lower of $1.05 or the current Market Price.
- Note ranks senior to all other outstanding and future indebtedness except for permitted liens.
Cosmos Health Inc. entered into a massive $300 million senior secured convertible promissory note offering to an institutional investor, with 72.5% of proceeds earmarked for purchasing cryptocurrency as a treasury asset. The deal includes significant dilution via conversion rights and requires a shareholder vote to increase authorized share counts significantly.
🚩 Red Flags
- Extreme Dilution Risk: The notes are convertible into common stock at the lower of Conversion Price or Market Price, and interest is payable in shares.
- High Leverage/Debt Load: A $300M debt facility for a micro-cap company represents massive potential liability.
- Speculative Asset Allocation: 72.5% of proceeds are tied to cryptocurrency acquisition, introducing extreme volatility risk to the balance sheet.
- Control Issues: The investor has rights to participate in up to 25% of future equity/equity-linked financing for three years.
- Significant Share Increase: Requesting authorization for 1.5 billion common shares suggests massive upcoming dilution.
📋 Key Facts
- Maximum aggregate principal amount of $300,000,000 in 9% original issue discount senior secured convertible promissory notes.
- Initial Note of $8,000,000 expected to close on August 6, 2025.
- 72.5% of net proceeds are designated to acquire 'Note Purchased Crypto' as a treasury asset.
- Interest is payable in shares of common stock (convertible into equity), with an option for cash interest.
- Default interest rate increases to 16% upon Event of Default.
- Company must call an annual meeting within 60 days to increase authorized shares to 1.5 billion Common and 300 million Preferred.
- Placement Agent (Curvature Securities, Inc.) to receive a 6.0% cash fee.
Cosmos Health Inc. has received a second 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share. The company must maintain a closing bid price of at least $1.00 for ten consecutive business days before November 3, 2025, to avoid delisting.
🚩 Red Flags
- Repeated failure to meet Nasdaq minimum bid price requirements
- Risk of delisting from the Nasdaq Capital Market if compliance is not met by November 3, 2025
- History of non-compliance (first notice issued in November 2024)
📋 Key Facts
- Nasdaq granted an additional 180-day compliance period through November 3, 2025.
- The deficiency relates to Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement.
- The company previously failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days as of November 6, 2024.
- Compliance requires the closing bid price to be at least $1.00 per share for ten (10) consecutive business days.
Cosmos Health Inc. announced on February 18, 2025, that it will not proceed with a planned offering under its existing Form S-1 Registration Statement. The company intends to wait until after the filing of its Annual Report for the fiscal year ended December 31, 2024, before making further decisions regarding offerings.
🚩 Red Flags
- Cancellation of a planned securities offering can indicate difficulties in securing capital or unfavorable market conditions for the issuer.
- Delaying offering decisions until after the 10-K filing suggests that the company's financial position (as detailed in the upcoming annual report) is a critical factor in its ability to raise funds.
📋 Key Facts
- Company decided not to proceed with an offering under its current Form S-1 Registration Statement as of February 18, 2025.
- The decision is tied to the upcoming filing of the Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
- The company will delay any potential offering decisions until after the 10-K is filed.
Cosmos Health Inc.'s subsidiary, CosmoFarm S.A., entered into a secured bond agreement with a European bank on January 27, 2025. The loan is valued at €2,200,000 (approx. $2,293,830) and is intended for strategic growth and working capital.
🚩 Red Flags
- Use of proceeds includes 'working capital,' which can sometimes indicate liquidity constraints in micro-cap companies.
- The debt is 'secured,' meaning assets are pledged as collateral to the lender.
📋 Key Facts
- Subsidiary CosmoFarm S.A. entered into a secured bond agreement on January 27, 2025.
- Loan amount: €2,200,000 (approximately $2,293,830).
- The debt is structured as a secured bond with a European bank.
- Proceeds are earmarked for strategic growth initiatives and general corporate purposes/working capital.
Cosmos Health Inc. entered into an exclusive worldwide patent and technology license agreement with DocPharma Single SA, a related party, for cancer treatment patents. The deal includes significant upfront and annual royalty payments over a 20-year term.
🚩 Red Flags
- Related-party transaction involving a significant licensing agreement.
- High fixed cash outflows (EUR 350,000 annually) regardless of sales during the 'Start-Up Term' through 2030.
- Potential for conflict of interest given the related-party status of the Licensor.
📋 Key Facts
- Agreement effective date: December 31, 2024.
- Licensor (DocPharma Single SA) is identified as a related party.
- License covers at least one of two patents for cancer treatment (filed in 2016 and 2017).
- The Company has an optional buy-out right for EUR 7,500,000 (EUR 4M for Patent 1; EUR 3.5M for Patent 2).
- Initial payment of $500,000 was due by year-end 2024.
- Fixed annual royalty of EUR 350,000 from 2025 to 2030 (Start-Up Term).
- Post-2030 royalty: 1.5% of annual Net Sales for Licensed Products.
- License is exclusive and worldwide with sublicensing rights.
Cosmos Health Inc. held its Annual Meeting of Shareholders on November 19, 2024, where shareholders approved several key measures including the election of directors and a new equity incentive plan. Most notably, shareholders authorized the Board of Directors to execute reverse stock splits at their discretion.
🚩 Red Flags
- Authorization of reverse stock splits: This is a significant red flag often used to maintain Nasdaq listing compliance regarding minimum bid price requirements.
- Warrant inducement: Approval of share issuance via warrants can lead to future dilution for existing shareholders.
📋 Key Facts
- Annual Meeting held on November 19, 2024.
- Quorum reached with 11,380,976 shares voted (approx. 54% of outstanding shares).
- Shareholders approved the issuance of common stock pursuant to certain Common Stock Purchase Warrants (70.41% affirmative).
- Shareholders approved the Company's 2024 Omnibus Equity Incentive Plan (78.25% affirmative).
- Shareholders authorized the Board to effect reverse stock splits at their discretion with 92.42% affirmative vote.
Cosmos Health Inc. received a non-compliance notice from Nasdaq due to its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has 180 days to regain compliance and has explicitly stated it intends to perform a reverse stock split if necessary.
🚩 Red Flags
- Delisting notice from Nasdaq (non-compliance with minimum bid price).
- Planned reverse stock split mentioned as a remedial action, which often leads to further dilution or downward pressure in micro-cap stocks.
- Failure to maintain $1.00 minimum bid price indicates significant recent share price depreciation.
📋 Key Facts
- Received non-compliance letter from Nasdaq on November 6, 2024.
- Violation of Nasdaq Listing Rule 5550(a)(2) regarding minimum bid price of $1.00.
- The company has a 180-calendar day period from November 6, 2024, to regain compliance.
- Compliance requires the closing bid price to be at least $1.00 for ten consecutive business days.
- Management intends to effect a reverse stock split if compliance is not achieved through other means.
Cosmos Health Inc. entered into an inducement offer with a warrant holder to exchange existing warrants for new, highly dilutive equity instruments. The transaction involves the issuance of millions of new warrants and series A/B warrants in exchange for cash exercise of previous warrants.
🚩 Red Flags
- Extreme dilution: The issuance of new warrants is at a 200% coverage rate relative to previous issuances.
- Complex warrant structure: Multiple layers of warrants (Series A, Series B, and 2024 New Warrants) create significant future overhang.
- Unregistered securities offering: Reliance on private placement exemptions often indicates difficulty accessing public markets for capital.
- Potential 'Death Spiral' characteristics: The use of inducement offers to restructure debt/warrants via massive equity issuance is a common tactic in distressed micro-caps.
📋 Key Facts
- The Holder will receive 2024 New Warrants to purchase up to 9,748,252 shares of common stock.
- The 2024 New Warrants have an exercise price of $0.95 per share.
- The Company will issue Series A Warrants (100% coverage) and Series B Warrants (100% coverage) to the Holder.
- The transaction is being conducted via unregistered sales under Sections 3(a)(9) and 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
- A.G.P./Alliance Global Partners acted as financial advisor, earning a 6% fee on gross proceeds plus legal expenses.
Cosmos Health Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The company achieved the necessary closing bid price for ten consecutive business days between July 5 and July 18, 2024.
🚩 Red Flags
- Historical delisting risk (the company was previously in non-compliance since March 2024).
📋 Key Facts
- Company regained compliance with Nasdaq Listing Rule 5550(a)(2) on July 19, 2024.
- Compliance was achieved by maintaining a closing bid price of $1.00 or greater for ten consecutive business days (July 5, 2024 – July 18, 2024).
- The deficiency originated from a March 20, 2024, notice regarding failure to maintain a $1.00 minimum bid price.
- Nasdaq has declared the matter closed.
Cosmos Health Inc. is facing significant regulatory and auditing crises, including a Nasdaq delisting notice due to delinquent 10-K and 10-Q filings and the dismissal of its auditor, KPMG. The filing reveals a direct disagreement between the company and KPMG regarding potential illegal acts related to third-party consignment transactions.
🚩 Red Flags
- Delisting notice from Nasdaq for failure to file periodic reports (10-K and 10-Q).
- Auditor change involving a major firm (KPMG) and subsequent disagreement over 'illegal acts'.
- Significant delay in financial reporting (delinquent FY2023 Annual Report).
- Disagreement between the company and auditor regarding audit scope and potential illegalities.
📋 Key Facts
- Nasdaq issued a written notice on May 21, 2024, stating the company is non-compliant due to failure to file the FY2023 Form 10-K and the Q1 2024 Form 10-Q.
- The company has until June 17, 2024, to submit a plan to regain compliance with Nasdaq Listing Rule 5810(b).
- KPMG was dismissed as the independent auditor effective April 26, 2024, after being unable to complete the FY2023 audit on time.
- RBSM LLP was appointed as the new independent registered public accounting firm on May 21, 2024.
- KPMG issued a letter to the SEC alleging disagreements regarding transactions with a third-party consignment vendor that suggested 'an illegal act may have occurred.'
- The Company disputes KPMG's characterization of the disagreement, stating an independent inventory count on April 30, 2024, substantiated the transactions.
Cosmos Health Inc. has dismissed its independent auditor, KPMG, following a dispute regarding audit procedures and potential illegal acts. The company is replacing KPMG with RBSM LLP to complete the 2023 fiscal year audit.
🚩 Red Flags
- Auditor change combined with allegations of 'illegal acts' by the outgoing auditor
- Failure to file Form 10-K for fiscal year 2023 within SEC deadlines due to audit suspension
- Direct disagreement between management/Audit Committee and KPMG regarding financial reporting integrity
- Significant dispute over inventory account transactions with a third-party vendor
📋 Key Facts
- KPMG was dismissed as the Company's independent registered public accounting firm effective April 26, 2024.
- KPMG stated in a letter to the SEC that they identified transactions with a third-party consignment vendor suggesting an 'illegal act may have occurred'.
- The company disputes KPMG's characterization, claiming KPMG only raised concerns regarding inventory accounts and related transactions.
- The dispute resulted in KPMG suspending all audit work on April 10, 2024, preventing the timely filing of the Form 10-K for fiscal year 2023.
- RBSM LLP was appointed as the new independent auditor on April 29, 2024.
- The company claims an independent inventory count conducted on April 30, 2024 substantiated the transactions in question.
Cosmos Health Inc. has filed an amendment to its 8-K reporting the dismissal of KPMG as its independent auditor, effective immediately. The filing reveals a significant dispute where KPMG alleges potential illegal acts involving third-party consignment vendors, while the Company denies these allegations and claims the disagreement stems from inventory accounting procedures.
🚩 Red Flags
- Auditor change combined with allegations of 'illegal acts' (Red Flag Escalator).
- Failure to file Form 10-K for fiscal year 2023 within SEC deadlines.
- Direct conflict between the auditor and the company regarding financial integrity/compliance.
- Suspension of audit work by a major firm (KPMG).
📋 Key Facts
- KPMG was dismissed as the independent registered public accounting firm on April 26, 2024.
- KPMG stated in a letter to the SEC that they identified transactions with a third-party consignment vendor suggesting an 'illegal act may have occurred'.
- The Company disputes KPMG's characterization, stating KPMG only raised concerns regarding inventory accounts and related transactions.
- KPMG suspended all audit work on April 10, 2024, preventing the timely filing of the Form 10-K for the fiscal year ended December 31, 2023.
- RBSM LLP was appointed as the new independent auditor on April 29, 2024.
- The Company claims an independent inventory count conducted on April 30, 2024 substantiated the transactions in question.
Cosmos Health Inc. has dismissed its independent registered accountant, KPMG Certified Auditors S.A., effective April 26, 2024. The dismissal occurred because KPMG was unable to complete the audit of the company's fiscal year 2023 financial statements on a timely basis.
🚩 Red Flags
- Auditor change combined with inability to complete timely audits is a significant red flag for financial reporting integrity and internal controls.
- Potential delay in filing annual reports (Form 10-K) due to the uncompleted audit of FY2023.
- The dismissal was driven by 'filing deadlines,' suggesting imminent non-compliance with SEC reporting timelines.
📋 Key Facts
- KPMG Certified Auditors S.A. (Athens, Greece) dismissed effective April 26, 2024.
- The dismissal was prompted by KPMG's inability to complete the audit for the fiscal year ended December 31, 2023 on a timely basis.
- KPMG had been appointed as the independent auditor on August 7, 2023.
- The company claims there were no disagreements with KPMG regarding accounting principles or practices prior to dismissal.
Cosmos Health Inc. entered into a Rights Agreement with Globex Transfer, LLC to implement a shareholder rights plan (poison pill). The plan is designed to prevent any person or group from acquiring 20% or more of the company's common stock without Board approval.
🚩 Red Flags
- Implementation of a 'Poison Pill' (Shareholder Rights Plan) often indicates the company is preparing for or defending against a hostile takeover attempt.
- Potential for massive dilution of existing shareholders if an acquiring person triggers the flip-in provision.
📋 Key Facts
- Entered into a Rights Agreement on April 22, 2024.
- The plan triggers if an 'Acquiring Person' reaches 20% beneficial ownership.
- Upon a trigger event, rights allow holders to purchase common shares at a significant discount (the market price is effectively doubled via the flip-in mechanism).
- Exercise price for each Right is $0.001 per share.
- The Rights Agreement is set for a period of five years, subject to shareholder ratification.
Cosmos Health Inc. received a notification from Nasdaq on April 17, 2024, stating the company is non-compliant with Listing Rule 5250(c)(1) due to failure to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The company has 60 days to submit a compliance plan.
🚩 Red Flags
- Delisting risk: Failure to file periodic financial reports (Form 10-K) is a primary trigger for Nasdaq delisting.
- Reporting delay: The company has failed to meet its mandatory SEC filing deadline, indicating potential internal control or accounting issues.
📋 Key Facts
- Received Nasdaq notification of non-compliance on April 17, 2024.
- Reason for non-compliance: Failure to file Form 10-K for the period ended December 31, 2023.
- The company has 60 calendar days from the notice date to submit a plan to regain compliance.
- Nasdaq may grant up to 180 days from the prescribed due date of the 10-K to regain compliance if the plan is accepted.
Cosmos Health Inc. received a non-compliance notice from Nasdaq due to its stock price falling below the $1.00 minimum bid requirement for 30 consecutive business days. The company has 180 days to regain compliance and is considering a reverse stock split if necessary.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq minimum bid rule
- Potential upcoming reverse stock split (often dilutive or signal of distress)
- Multiple 8-K items in a single filing (3.01 and 8.01)
📋 Key Facts
- Received Nasdaq non-compliance letter on March 20, 2024.
- Failure to maintain minimum bid price of $1.00 per share for 30 consecutive business days (Nasdaq Listing Rule 5550(a)(2)).
- Compliance period: 180 calendar days from March 20, 2024.
- Requirement to regain compliance: Closing bid price must be at least $1.00 for 10 consecutive business days.
- Company intends to effect a reverse stock split if it cannot otherwise regain compliance.
Cosmos Health Inc. completed the acquisition of a 10-drug generic portfolio from a related party for approximately $3.5 million (€3.2 million). The transaction is intended to expand the company's presence in the global generic drugs market.
🚩 Red Flags
- Related-party transaction involving the acquisition of assets for $3.5 million
- Potential for non-arm's length pricing in a micro-cap context
📋 Key Facts
- Acquisition date: January 18, 2024
- Asset acquired: Licenses and rights of a portfolio of 10 generic drugs
- Transaction value: €3.2 million (approx. $3.5 million USD)
- Counterparty: A related party